Search global stocks & ETFs...Ctrl K
Learn Mode
ADMA Biologics IncADMA
$8.71
-$0.10 (-1.135%)
$8.70
-$0.0075 (-0.086%)
ADMA
Stock Profile
08-12
Recommended Metric
Score Card
Explore Scores Tab
4.39
Very Good
Valuation Score
Key Score
4.00
Good
Management
2.00
Bad
Growth
2.00
Bad
Profitability
2.00
Bad
Fin. Health
3.00
Average
Dividends
--
--
Analyst
1.00
Very Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending Jun 28, 2027
Current
$8.71
Baseline
High
$22.05
▲
153.16%
Avg
$17.95
▲
106.11%
Low
$12.12
▲
39.15%
Analyst Ratings based on 11 Analysts
Strong Buy
218%
Buy
764%
Hold
218%
Sell
000%
Strong Sell
000%
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 647 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.Read More
Stock News
View All Updates
News100%Bearish
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17
3dBenzinga
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
4dYahoo
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
5dYahoo
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
1wYahoo
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
1wYahoo
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
1wYahoo
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
2wYahoo
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
3wYahoo
3 Biotech Firms With Major Potential Catalysts in the Coming Months
3wYahoo
ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations
3wYahoo
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know
4wYahoo
Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts
5wYahoo
Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?
6wYahoo
US High Growth Tech Stocks with Promising Potential
6wYahoo
New Strong Sell Stocks for June 3rd
6wYahoo
ADMA Biologics (ADMA) Valuation After 2026 Guidance Reset And BIVIGAM Headwinds
6wYahoo
ADMA Biologics (ADMA) Receives FDA Label Expansion for ASCENIV
6wYahoo
Is ADMA Biologics, Inc. (ADMA) Among the Best Russell 2000 Stocks to Invest In According to Hedge Funds?
6wYahoo
ADMA Biologics: Longstanding Bull Hits The Reset Button After Murky Q1 Earnings
7wSeekingAlpha
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
7wYahoo
Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
7wYahoo
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
8wYahoo
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
8wYahoo
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
8wYahoo
Stanley Druckenmiller Dumps Amazon And Alphabet While Loading Up On Commodities, Argentina And Biotech
8wBenzinga
How Channel Stuffing Probes and ASCENIV’s Pediatric Expansion Will Impact ADMA Biologics (ADMA) Investors
9wYahoo
Here’s What Analysts Think About ADMA Biologics (ADMA)
9wYahoo
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
9wYahoo
New Strong Sell Stocks for May 14th
9wYahoo
Canaccord Cuts PT on ADMA Biologics Inc. (ADMA) But Remains a Buy on Shares
9wYahoo
ADMA Biologics Investors Should Contact Block & Leviton to Possibly Recover Losses Through The Firm's Investigation
9wFinnhub
New Strong Sell Stocks for May 11th
9wYahoo
Canaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18
10wBenzinga
ADMA Biologics Investigated for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
10wFinnhub
12 Health Care Stocks Moving In Thursday's Pre-Market Session
10wBenzinga
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
10wBenzinga
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20
10wBenzinga
Why Kulicke And Soffa Industries Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
10wBenzinga
ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
10wSeekingAlpha
Transcript : ADMA Biologics, Inc., Q1 2026 Earnings Call, May 06, 2026
10wFinnhub
ADMA Biologics (NASDAQ:ADMA) Shares Plunge on Q1 Miss and Revenue Guidance Cut
10wChartMill
What's going on in today's after hours session
10wChartMill
Adma Biologics: Q1 Earnings Snapshot
10wFinnhub
12 Health Care Stocks Moving In Wednesday's After-Market Session
10wBenzinga
Earnings Scheduled For May 6, 2026
10wBenzinga
ADMA Biologics Sees FY2026 Sales $530.000M-$560.000M vs $632.367M Est
10wBenzinga
ADMA Biologics Q1 Adj. EPS $0.17 Misses $0.20 Estimate, Sales $114.493M Miss $141.800M Estimate
10wBenzinga
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
10wFinnhub
ADMA Biologics Announces FDA Approval Of The Company's Supplemental Biologics License Application Submitted Under Section 351(a) Of The Public Health Service Act For ASCENIV
10wBenzinga
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older
10wFinnhub